Huang Y - Search Results

1

Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.

Jiang Y, Li X, Hou J, Huang Y, Wang X, Jia Y, Wang Q, Xu W, Zhang J, Zhang Y. Jiang Y, et al. Among authors: huang y. Eur J Med Chem. 2018 Jan 1;143:334-347. doi: 10.1016/j.ejmech.2017.11.074. Epub 2017 Dec 1. Eur J Med Chem. 2018. PMID: 29202398

2

Enhanced anticancer activity of 5-FU in combination with Bestatin: Evidence in human tumor-derived cell lines and an H22 tumor-bearing mouse.

Li J, Wang X, Hou J, Huang Y, Zhang Y, Xu W. Li J, et al. Among authors: huang y. Drug Discov Ther. 2015 Feb;9(1):45-52. doi: 10.5582/ddt.2015.01006. Drug Discov Ther. 2015. PMID: 25788051 Free article.

3

Design, synthesis, and antitumor evaluation of histone deacetylase inhibitors with L-phenylglycine scaffold.

Zhang Y, Li X, Hou J, Huang Y, Xu W. Zhang Y, et al. Among authors: huang y. Drug Des Devel Ther. 2015 Oct 8;9:5553-67. doi: 10.2147/DDDT.S94037. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26504374 Free PMC article.

4

Novel leucine ureido derivatives as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.

Ma C, Cao J, Liang X, Huang Y, Wu P, Li Y, Xu W, Zhang Y. Ma C, et al. Among authors: huang y. Eur J Med Chem. 2016 Jan 27;108:21-27. doi: 10.1016/j.ejmech.2015.11.021. Epub 2015 Nov 26. Eur J Med Chem. 2016. PMID: 26629857

5

Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.

Jiang Y, Li X, Hou J, Huang Y, Jia Y, Zou M, Zhang J, Wang X, Xu W, Zhang Y. Jiang Y, et al. Among authors: huang y. Eur J Med Chem. 2016 Oct 4;121:649-657. doi: 10.1016/j.ejmech.2016.05.068. Epub 2016 Jun 1. Eur J Med Chem. 2016. PMID: 27322756

6

Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.

Jiang Y, Hou J, Li X, Huang Y, Wang X, Wu J, Zhang J, Xu W, Zhang Y. Jiang Y, et al. Among authors: huang y. Bioorg Med Chem. 2016 Nov 15;24(22):5787-5795. doi: 10.1016/j.bmc.2016.09.033. Epub 2016 Sep 14. Bioorg Med Chem. 2016. PMID: 27670098

7

Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.

Li X, Zhang Y, Jiang Y, Wu J, Inks ES, Chou CJ, Gao S, Hou J, Ding Q, Li J, Wang X, Huang Y, Xu W. Li X, et al. Among authors: huang y. Eur J Med Chem. 2017 Jul 7;134:185-206. doi: 10.1016/j.ejmech.2017.03.069. Epub 2017 Mar 30. Eur J Med Chem. 2017. PMID: 28415009 Free PMC article.

8

Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.

Zang J, Liang X, Huang Y, Jia Y, Li X, Xu W, Chou CJ, Zhang Y. Zang J, et al. Among authors: huang y. J Med Chem. 2018 Jun 28;61(12):5304-5322. doi: 10.1021/acs.jmedchem.8b00384. Epub 2018 Jun 7. J Med Chem. 2018. PMID: 29787262

9

Synthesis and biological evaluation of novel benzofuroxan-based pyrrolidine hydroxamates as matrix metalloproteinase inhibitors with nitric oxide releasing activity.

Zhang H, Wang X, Mao J, Huang Y, Xu W, Duan Y, Zhang J. Zhang H, et al. Among authors: huang y. Bioorg Med Chem. 2018 Aug 15;26(15):4363-4374. doi: 10.1016/j.bmc.2018.06.023. Epub 2018 Jun 18. Bioorg Med Chem. 2018. PMID: 30093347

10

LJNK, an indoline-2,3-dione-based aminopeptidase N inhibitor with promising antitumor potency.

Hou J, Jin K, Li J, Jiang Y, Li X, Wang X, Huang Y, Zhang Y, Xu W. Hou J, et al. Among authors: huang y. Anticancer Drugs. 2016 Jul;27(6):496-507. doi: 10.1097/CAD.0000000000000351. Anticancer Drugs. 2016. PMID: 26872309

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81,960 results

Search Page

Filters